
EKGGF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for EKGGF and 80,000+ other tickers.
See exactly how EKGGF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EKGGF and 80,000+ other tickers.
CardioComm Solutions, Inc., established in 1989 and based in Toronto, Canada, specializes in developing advanced technological solutions for cardiac monitoring. The company delivers both sophisticated software and hardware products, as well as core laboratory reading services, specifically designed for electrocardiogram (ECG) and ambulatory arrhythmia detection systems. These comprehensive offerings cater to both the medical sector and individual consumers across the globe. At the heart of CardioComm's operations is proprietary technology that underpins the entire ECG workflow: from initial…

Toronto, Ontario--(Newsfile Corp. - June 8, 2026) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a provider of consumer heart monitoring, remote patient monitoring and medical electrocardiogram ("ECG") software solutions, is pleased to announce that it has entered into a strategic collaboration, joint development and intellectual property agreement with Predictiv AI Inc. ("Predictiv AI") of North York, Ontario. The agreement establishes a framework under which the companies may identify, assess and, where mutually approved, pursue specific projects involving healthcare software, medical software, artificial intelligence, automated analytics, remote patient monitoring, clinical decision support, biosignal interpretation, predictive analytics, workflow optimization and software as a medical device applications.

Toronto, Ontario--(Newsfile Corp. - May 8, 2026) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a leader in consumer heart monitoring, remote patient monitoring, and medical electrocardiogram ("ECG") software solutions, announces that it has elected to rely on Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers and move to semi-annual financial reporting ("SAR"). Coordinated Blanket Order 51-933 allows eligible venture issuers listed on the TSX Venture Exchange (the "TSXV") to voluntarily move from a quarterly to a semi-annual financial reporting framework.

Funding will be used to a advance GEMS Flex And 14-Day Holter/LTCM ECG Platform Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, is pleased to announce that it has received approval from the TSX Venture Exchange for its November 3, 2025 announced loan agreement dated November 3, 2025 (the "Loan Agreement") representing aggregate funding of $512,000. The Loan Agreement provides new working capital to complete and commercialize the Company's GEMS FLEX and 14-day Holter and Event long term continuous monitoring ("LTCM") ECG software platform (the "Flagship Product").

Toronto, Ontario--(Newsfile Corp. - November 4, 2025) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announces that it has terminated a royalty agreement announced October 1, 2025 (the "Royalty Agreement) and entered into a loan agreement dated November 3, 2025 (the "Loan Agreement") with current debt lenders to the Company (the "Lenders") for aggregate funding of $512,000. A copy of the Loan Agreement has been filed by the Company on SEDAR+.

Funding to Support Commercial Launch of Flagship 14 Day Holter-Event GEMS Software Platform Toronto, Ontario--(Newsfile Corp. - October 1, 2025) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announces that it has entered into a royalty-based financing arrangement (the "Royalty Agreement") with current debt lenders to the Company (the "Lenders") in order secure new capital required to complete and commercialize the Company's new flagship GEMS FLEX and 14 day Holter and Event long term continuous monitoring ("LTCM") ECG software platform (the "Flagship Product"). The Royalty Agreement will also assist the Company in assuming all existing, interest-bearing loans.